Tradestie Institutional Equity Comparison Engine
VS vs VRAX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
VRAX Overall Edge
VRAX Captures Institutional Edge (1โ1 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Virax Biolabs Group Limited Ordinary Shares (VRAX) driven by superior Momentum & Technical while VS counters with relative strength in Growth & Margin. Fundamentally, VS trades at N/M Forward P/E with -136.2% operating margin (-24.7% YoY revenue) versus VRAX at N/M Forward P/E and -51515.2% operating margin (+684.9% YoY). In options structure, VS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against VRAX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VS N/M vs VRAX N/M Fwd P/E
Growth & Margin Winner
VS
Op Margin -136.2% vs -51515.2% ยท YoY -24.7% vs +684.9%
Momentum & Technical Winner
VRAX
1Y -59.5% vs -24.6% ยท 52W Pos 0% vs 2%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
VS
NASDAQ
Versus Systems Inc. Common Stock
Services-Computer Processing & Data Preparation
$0.57
-17.44% 1D
Market Cap
$4.3M
1M Return
-40.83%
1Y Return
-59.54%
Forward P/E
N/M
Unified AI Score
40.6 / 100
SELL
Tech 25.0
Fund 47.0
Flow 50.0
Mom 55.0
VRAX
NASDAQ
Virax Biolabs Group Limited Ordinary Shares
In Vitro & In Vivo Diagnostic Substances
$0.33
-12.89% 1D
Market Cap
$470,745
1M Return
-73.13%
1Y Return
-24.62%
Forward P/E
N/M
Unified AI Score
46.5 / 100
HOLD
Tech 45.0
Fund 50.0
Flow 50.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VS -59.54%
VRAX -24.62%
Spread: +34.92 pp (VRAX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
VS TTM Op. Margin: -136.2%
VRAX TTM Op. Margin: -51515.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VS vs VRAX. Trailing 12-month operating profitability (VS -136.2% vs VRAX -51515.2%) and valuation multiples (VS N/M vs VRAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VS | VRAX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.3M | $470,745 | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -24.7% | +684.9% | Higher Growth | VRAX |
| Operating Margin (TTM) Profitability | -136.2% | -51515.2% | Higher Margin | VS |
| Net Profit Margin Profitability | -112.8% | 0.0% | Higher Margin | VRAX |
| Return on Equity (ROE) Capital Efficiency | -69.2% | -78.6% | Higher ROE | VS |
| 52-Week Range Position Momentum | 0% ($1โ$2) | 2% ($0โ$13) | Stronger Trend | VRAX |
| Beta / 30D Volatility Risk Regime | 1.45ฮฒ ยท 78% Vol | -8.20ฮฒ ยท 162% Vol | Lower Realized Risk | VS |
| Unified Institutional Score Composite Signal | 40.6 / 100 (SELL) | 46.5 / 100 (HOLD) | Higher Composite | VRAX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VS vs VRAX Buy Guide
VS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
VRAX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VS nor VRAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.